Factors influencing the success of radioiodine therapy in patients with Graves' disease.
The first dose of radioiodine (I) does not always cure hyperthyroidism in patients with Graves' disease (GD). Our aim was to evaluate the factors influencing the success of I therapy. We reviewed the medical records of 724 patients who were first diagnosed with GD between 2005 and 2009 and were subsequently treated with I in a fixed-dose manner considering the thyroid volume (TV). TSH, fT(4), and fT(3) were measured. TV was measured by means of ultrasonography. Successful therapy was followed by euthyroidism or hypothyroidism. Out of 724 patients, 656 (90.5%) were successfully (Group 1) and 69 (9.5%) were unsuccessfully (Group 2) treated with the first dose of (131)I. In Group 1, the applied dose of (131)I was lower than that in Group 2 [626±107, 95% confidence interval (CI) 618-634, and 709±140, 95% CI 675-742 MBq, respectively; P<0.001]. At presentation, patients in Group 1 were younger than those in Group 2 (45.5±14.9, 95% CI 44.4-46.6, and 50.1±15.8, 95% CI 46.3-53.9 years, respectively; P=0.031). They had a lower fT(4) (54.9±26.1, 95% CI 52.9-56.9, and 72.1±34.1, 95% CI 63.9-80.3 pmol/l, respectively; P<0.001), a lower fT3 (20.9±8.2, 95% CI 20.3-21.5, and 23.9±8.2, 95% CI 21.9-25.9 pmol/l, respectively; P<0.001), and a smaller TV (21.5±13.2, 95% CI 20.2-22.8, and 35.6±22.3, 95% CI 28.2-42.9 ml, respectively; P<0.001). Before I therapy, patients in Group 1 had a lower fT(3) (9.6±6.0, 95% CI 9.2-10.1, and 11.3±7.6, 95% CI 9.5-13.2 pmol/l, respectively; P=0.038). Successfully treated GD patients were younger, less severely hyperthyroid, and had a smaller TV at presentation. They were also less severely hyperthyroid before I therapy.